Drug
Tildrakizumab For
Tildrakizumab For: highest development phase Post-Market, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tildrakizumab 100 mg Solution for Injection NCT04229836 | Post-Market | Plaque Psoriasis |
Latest
No recent events.
Follow Tildrakizumab For on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.